Fifty employees of Bharat Biotech test Covid-19 positive: Joint MD Ella

The firm is supplying Covaxin to 18 states, including AP, Haryana, Odisha, Assam, J&K, Tamil Nadu, Bihar, Jharkhand as well as Delhi

Suchitra Ella
Suchitra Ella, joint managing director, Bharat Biotech | Photo: Twitter
Press Trust of India New Delhi
2 min read Last Updated : May 14 2021 | 12:10 AM IST
Bharat Biotech’s Joint Managing Director Suchitra Ella’s tweet saying 50 of their employees tested positive for Covid received bouquets and brickbats from netizens with some saying Covaxin was saving lives while a few questioned as to why the staff were not vaccinated.

Referring to comments by some political bosses over Covid-19 vaccine Covaxin supply issues, Ella on Wednesday tweeted: “Quite disheartening to the teams to hear some states complaining about our intentions. 50 of our employees are off work due to covid, yet we continue to work under pandemic lockdowns 24x7 for U”.


Reacting to her tweet, one user wrote: “How come your 50 employees down with Covid? Were they not vaccinated? Also, why not hire more people on temporary basis?” Ella’s tweet got 9,373 likes and was retweeted by 2,564 people (at 10:30 am on May 13).

“Hi just wanted to say Thank you. Both my grandparents are over 75 & took their first jab 5 weeks back, both tested Covid-positive 2 weeks back. Low fever were their only symptoms, tested negative today, on the road to recovery with no major issues,” tweeted another netizen. “Thank you Bharat Biotech for your hard work and commitment on delivering vaccines every corner of India,” another user said.

Another user said, “If you say that your employees are sick of covid, it speaks volumes about efficacy of your vaccine.”

Ella said as many as 18 states received Covaxin though in smaller shipments.

The firm is supplying Covaxin to 18 states, including AP, Haryana, Odisha, Assam, J&K, Tamil Nadu, Bihar, Jharkhand as well as Delhi.

The other states are Chhattisgarh, Karnataka, Telangana, Tripura, Madhya Pradesh, Uttar Pradesh, Gujarat, Maharashtra and West Bengal.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusBharat BiotechCoronavirus Vaccine

Next Story